Related Experiment Video

Updated: Jun 8, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Anemia in heart failure: should we supplement iron in patients with chronic heart failure?

Elisabet E Kaldara-Papatheodorou1, John V Terrovitis, John N Nanas

  • 13rd Cardiology Department, University of Athens, School of Medicine, Greece.

Polskie Archiwum Medycyny Wewnetrznej
|September 25, 2010
PubMed

Insights

Anemia is linked to worse outcomes in congestive heart failure (CHF). Correcting anemia, particularly iron deficiency, may improve CHF patient prognosis, though optimal treatments require further study.

Area of Science:

  • Cardiology
  • Hematology
  • Internal Medicine

Background:

  • Anemia is a significant independent prognostic factor for morbidity and mortality in congestive heart failure (CHF) patients.
  • The link between anemia and adverse outcomes suggests potential benefits from anemia correction in CHF.
  • Large-scale randomized trial data on anemia correction's impact on CHF patient outcomes are currently limited.

Purpose of the Study:

  • To review current treatment options for anemia in patients with congestive heart failure.
  • To emphasize the role of iron deficiency correction in managing anemic CHF patients.
  • To discuss the efficacy of various therapeutic approaches, including erythropoietin and iron supplementation.

Main Methods:

  • Review of numerous clinical studies, encompassing both randomized and non-randomized trials.
  • Evaluation of studies assessing erythropoietin and iron supplementation for anemia in CHF.
  • Analysis of effects on patient symptoms and functional status.

Main Results:

  • Existing studies have evaluated the efficacy of erythropoietin and iron supplementation in anemic CHF patients.
  • The superiority of any single treatment approach (e.g., erythropoietin vs. iron) has not been definitively established.
  • Evidence suggests a strong association between anemia and poor prognosis in CHF.

Conclusions:

  • Anemia correction is a potential therapeutic strategy for improving outcomes in congestive heart failure.
  • Iron deficiency correction is a key focus for managing anemia in CHF patients.
  • Further research is needed to establish the most effective treatment strategies and confirm benefits.

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...